Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 9/20 | 0.39 |
| ▸ | ACACB | O00763 | 3/20 | 0.38 |
| ▸ | PPARD | Q03181 | 5/20 | 0.38 |
| ▸ | PPARA | Q07869 | 5/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575158 | 0.91 | PPARD (0.38) | PPARGPPARDPPARACYP2C9ALOX5 | |
| SCHEMBL4574795 | 0.90 | PPARG (0.38) | PPARGPPARDPPARACYP2C9TRPM8 | |
| SCHEMBL4575643 | 0.88 | DAGLA (0.40) | PPARGCYP2C9TRPM8ALOX5 | |
| SCHEMBL4576134 | 0.87 | PPARD (0.43) | PTGDR2PPARDPPARATRPV1MRGPRX4 | |
| SCHEMBL4575952 | 0.86 | PPARA (0.50) | PTGDR2PPARGPPARDPPARA | |
| SCHEMBL4575425 | 0.82 | NR1H2 (0.40) | TRPM8TRPV1 | |
| SCHEMBL4575153 | 0.81 | PPARA (0.40) | PTGDR2PPARGPPARDPPARACYP2C9 | |
| SCHEMBL4575412 | 0.81 | PPARD (0.46) | PTGDR2PPARGPPARDPPARACYP2C9 | |
| SCHEMBL4575465 | 0.81 | TSHR (0.42) | PPARGPPARDPPARA | |
| SCHEMBL4575187 | 0.81 | PPARA (0.38) | PTGDR2PPARGPPARDPPARACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | PTGDR2 332/4885PPARG 1/4885ACACB 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.